Mindset Pharma News Today

Mindset Pharma Inc. (OTCMKTS:MSSTF – Get Free Report) was the recipient of a significant increase in short interest during the month of October. As of October 15th, there was short interest totalling 3,300 shares, an increase of 17.9% from the September 30th total of 2,800 shares. Based on an average daily volume of 33,800 shares, […]

Mindset Pharma Inc. (OTCMKTS:MSSTF – Get Free Report) was the recipient of a significant increase in short interest in October. As of October 15th, there was short interest totalling 3,300 shares, an increase of 17.9% from the September 30th total of 2,800 shares. Based on an average daily trading volume, of 33,800 shares, the days-to-cover […]

VANCOUVER, British Columbia, Oct. 26, 2023 -- Mydecine Innovations Group Inc. , a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly...

Investorideas.com a global investor news source covering psilocybin and psychedelic health and wellness stocks releases a special news report featuring Kaya Holdings, Inc. . As psilocybin and other...

Pioneers and Innovators in Psilocybin Treatments (OTCQB: KAYS) (NASDAQ: CMPS) (NYSE: CYBN) (OTC: MSSTF)

Ovid Therapeutics (NASDAQ:OVID – Get Free Report) and Mindset Pharma (OTCMKTS:MSSTF – Get Free Report) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings. Profitability This table compares Ovid Therapeutics and Mindset […]

Clinical-stage biopharma company Reunion Neuroscience has received the FDA’s clearance on its Investigational New Drug (IND) application to begin a Phase 2 study of RE104, a novel serotonergic psychedelic compound aimed at treating postpartum depression (PPD.) 

Start-ups are tweaking psychedelic compounds to treat mental health conditions.

Start-ups are tweaking psychedelic compounds to treat mental health conditions.

Start-ups are tweaking psychedelic compounds to treat mental health conditions.